Key result
Serious adverse events affect ~60% of large core stroke patients, predominantly unrelated to thrombectomy.
Why the study?
Thrombectomy has shown efficacy in large core ischemic stroke, and although these patients may be predisposed to complications, comprehensive data on the role of serious adverse events in large core ischemic stroke remained scarce.
Does thrombectomy increase serious adverse events or affect 90-day functional outcomes in patients with large core ischemic stroke?
RCT (n=253)
Randomized
Does thrombectomy increase serious adverse events or affect 90-day functional outcomes in patients with large core ischemic stroke?
In patients with large core ischemic stroke, serious adverse events are common and negatively impact 90-day functional outcomes, though they are predominantly unrelated to thrombectomy.
Answers are grounded in this paper and cite their sources.
SAEs merit monitoring in large core thrombectomy; supports established risk factors but leaves open causal links and mitigation trials.
BACKGROUND: Serious adverse events (SAEs) affect outcomes in patients with stroke. Thrombectomy is the standard treatment for large vessel occlusion and has recently shown efficacy in patients with large core ischemic stroke. However, although these patients may be particularly predisposed to complications, comprehensive data on the role of SAEs in large core ischemic stroke remain scarce. METHODS: To investigate the role of SAEs in large core ischemic stroke and thrombectomy, we performed a post hoc analysis of the randomized, controlled TENSION trial (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window). SAEs were defined by the International Council for Harmonization–Good Clinical Practice and coded by organ system using Medical Dictionary for Regulatory Activities terminology. We analyzed the frequency and distribution of SAEs. Using multivariable logistic regression, we examined predictors of SAEs and their impact on the likelihood of achieving a favorable functional outcome at 90 days. RESULTS: Among 253 patients, 152 experienced a total of 240 SAEs. SAEs most commonly involved nervous system disorders (47.1%), followed by infections (22.9%) and cardiovascular complications (15%). SAEs were predominantly classified as nonthrombectomy-related (93.8%). Multivariable logistic regression revealed that higher National Institutes of Health Stroke Scale Scores, increased infarct volume, and advanced age were associated with SAEs, whereas thrombectomy treatment was not. Absence of SAEs was related to better functional outcome. In the thrombectomy subgroup, SAE occurrence was the only factor associated with a reduced likelihood of achieving a favorable functional outcome. CONCLUSIONS: Our findings reconfirm known SAE risk factors and show a high frequency of SAEs also for patients with extended stroke lesions. SAEs are predominantly nonthrombectomy-related and independent of the type of acute stroke therapy. In large core ischemic stroke, their occurrence negatively impacts functional outcome and may offset the benefit of thrombectomy. Due to limited sample size, our findings must be considered exploratory, warranting further analyses. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03094715.
No takes yet. Share an insight, caveat, or question.
Link et al. (2026) conducted an RCT in Large core ischemic stroke (n=253). Thrombectomy vs. Without thrombectomy was evaluated on Serious adverse events (SAEs) and favorable functional outcome at 90 days. Serious adverse events occurred in 60.1% (152/253) of large core stroke patients, were mostly nonthrombectomy-related, and reduced favorable 90-day functional outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: